Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers
- None.
- None.
Insights
The ongoing development of MTX110 by Biodexa Pharmaceuticals represents a pivotal moment in the treatment of Diffuse Midline Glioma and Recurrent Glioblastoma, two particularly aggressive brain cancers. The repositioning of panobinostat, a drug initially approved for multiple myeloma, through Convection Enhanced Delivery technology, signifies a novel approach to drug delivery in oncology. The ability to bypass the blood-brain barrier and directly target the tumor site could potentially revolutionize the standard of care for these patients.
From a research perspective, the reported median overall survival rates in early trials, notably higher than historical rates, suggest a potential breakthrough in a therapeutic area with limited options. However, it's important to remain cautious as these are early-phase trials and the sample sizes are typically small. The progression-free survival data expected in Q2 2024 will be a critical milestone for Biodexa, as it will provide a more robust indicator of the drug's efficacy. If the results are positive, this could lead to an acceleration in the drug's development pathway and possibly attract partnership opportunities or additional investment to fund further trials.
The treatment landscape for DMG and rGBM is notably challenging due to the aggressive nature of these tumors and the difficulty in achieving effective drug delivery. MTX110's utilization of CED technology is a significant advancement in this context, as it allows for higher concentrations of the drug at the tumor site, potentially improving efficacy while reducing systemic side effects. This targeted approach is a key differentiator and could lead to improved survival rates and quality of life for patients.
Furthermore, the extension of median overall survival in early trials of MTX110 is impressive, particularly in a patient population with such poor prognoses. For clinicians, these developments could mean a new tool in the arsenal against these formidable cancers. However, the long-term benefits and potential side effects of this delivery method will need to be closely monitored in subsequent trials to fully understand the clinical implications.
For investors and stakeholders in the biopharmaceutical sector, Biodexa's progress with MTX110 is of significant interest. The high unmet need and the lack of effective treatments for DMG and rGBM represent a substantial market opportunity. The successful development and commercialization of MTX110 could position Biodexa as a leader in this niche market segment.
Investor sentiment is likely to be influenced by the upcoming results for progression-free survival. Positive data could lead to stock price appreciation due to the potential of MTX110 to meet a critical treatment gap. Conversely, any setbacks in the trial could impact investor confidence and Biodexa's market valuation. It's essential for investors to monitor these developments closely, as they could have significant implications for Biodexa's financial outlook and strategic positioning within the oncology market.
Topline Results For Progression-Free Survival Expected In Q2 2024
CARDIFF, UK / ACCESSWIRE / March 28, 2024 / Biodexa Pharmaceuticals (NASDAQ:BDRX) ("Biodexa"), an acquisition-focused biopharmaceutical company, is developing MTX110 for the treatment of Diffuse Midline Glioma (DMG) in pediatric patients and for Recurrent Glioblastoma (rGBM) in adults; two aggressive brain cancers with universally poor prognoses.
The company says early trials of MTX110 in both cancers show promise in extending survival rates beyond those reported in previously published studies.
DMG tumors are highly aggressive grade IV tumors that exhibit a propensity to infiltrate the surrounding tissues. Commonly found throughout the brainstem, these tumors pose significant challenges in treatment. The median overall survival rate for individuals - typically children diagnosed with diffuse midline glioma is less than one year - generally ranges from eight to 11 months. A small percentage, approximately
Glioblastoma (GBM) is the most prevalent malignant primary tumor of the central nervous system in adult patients and is known for its aggressive nature and tendency to invade surrounding tissues. Although GBM is rare, it carries a high fatality rate, with an incidence of 3.44 per 100,000 individuals and a median overall survival of only eight months, regardless of treatment. The five-year survival rate stands at a mere
Both cancers have a high mortality rate and a high unmet need. Biodexa is hoping to meet these needs as it further develops MTX110. The main chemotherapy agent of MTX110, panobinostat, was originally used to treat multiple myeloma and received FDA approval in 2015. The company is currently reworking the chemotherapy agent by changing its delivery method and leveraging Convection Enhanced Delivery (CED) technology.
Researchers discovered that the original formulation of panobinostat was capable of blocking enzymes involved in cancer cell growth, exhibiting high potency against brain stem tumor cells in vitro and in vivo. However, the original oral tablet form is both insoluble and incapable of crossing the blood-brain barrier at therapeutic levels - making it an ineffective treatment method for brain cancers.
The distinctive feature of MTX110 is that it combines a water-soluble form of panobinostat with a CED device that delivers the drug directly to the brain tumor through a surgically implanted catheter and refillable pump. Biodexa says the drug achieves high drug concentrations within the tumor while limiting systemic exposure.
The proof-of-concept phase 1 clinical trial of MTX110 took place at the University of California San Francisco with patients battling DMG. The trial produced promising results with a median overall survival of 26 months, compared to a historical overall survival rate of 10 months. Similarly, a phase 1 trial involving newly diagnosed DMG patients at Columbia University Irving Medical Center also had encouraging outcomes, with MTX110 treatment increasing median overall survival to 16 months from a historical overall survival rate of 10 months.
The findings from this study will be presented at the 21st International Symposium on Pediatric Neuro-Oncology (June 28 - July 2, 2024), and the company may potentially continue developing the drug in this indication in a phase 2 study.
Biodexa reports that the ongoing MAGIC-G1 phase 1 trial in recurrent GBM patients at Duke Cancer Institute and Baptist MD Anderson Cancer Center is currently showing considerable progress with completion of recruitment for cohort A of the study. The first patient survived for 12 months, and three patients currently remain in the study. The expected topline results for progression-free survival from cohort A will be available in Q2 of 2024. The retrospective analysis of 299 patients with similar recurrent GBM disease showed a median overall survival of only 6.5 months after the recurrence of GBM cancer.
Biodexa is hopeful MTX110 could potentially help extend patient life, offering much-needed hope to patients and their families. The company's delivery method may also help prevent full-body exposure, which could minimize negative side effects. For cancers with such high mortality rates, any amount of extra time with a better quality of life is groundbreaking.
Click here for more information on Biodexa Pharmaceuticals: https://redingtonvirtual.com/bdrx-benzinga-24032/
Featured photo sourced from Shutterstock
Important notice, please read: Certain statements in this material are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," and "intend," among others. These forward-looking statements are based on Biodexa's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval, and commercialization of new products. Biodexa does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission (the "SEC") in March 2023, and periodic reports filed with the SEC on or after the date thereof. All Biodexa's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof. This is not a solicitation of any offer to buy or sell. Redington, Inc. is paid by Biodexa Pharmaceuticals PLC to provide investor relations services, and its employees or members of their families may from time to time own an equity interest in companies mentioned herein.
Contact:
Stephen Stamp, CEO, CFO
ir@biodexapharma.com
SOURCE: Biodexa Pharmaceuticals Plc
View the original press release on accesswire.com
FAQ
What is Biodexa Pharmaceuticals developing for Diffuse Midline Glioma (DMG) and Recurrent Glioblastoma (rGBM)?
What is the main chemotherapy agent in MTX110?
What delivery method is used for MTX110?
What were the results of the phase 1 clinical trial of MTX110 for DMG patients?
What is the status of the ongoing MAGIC-G1 phase 1 trial for recurrent GBM patients?
